NIH chooses not to use ‘march-in rights’ in prostate drug row
The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 March 2023 NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.
19 May 2022 The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.